Literature DB >> 2897398

Penicillin resistance and defective lysis in clinical isolates of pneumococci: evidence for two kinds of antibiotic pressure operating in the clinical environment.

P Moreillon1, A Tomasz.   

Abstract

Seventy percent of clinical isolates of penicillin-resistant pneumococci also exhibit defective lysis when treated with penicillin exceeding the minimal inhibitory concentration (MIC). To provide a possible explanation for the frequent association of these two traits, we exposed penicillin-susceptible pneumococci to two kinds of antibiotic pressures in the laboratory. Treatment of cultures with cycles of high concentrations of penicillin (20 X MIC) followed by growth of the survivors in drug-free medium selected for lysis-defective mutants that died only slowly during antibiotic treatment but had unchanged MICs. Exposure to sustained, low levels of penicillin produced resistant mutants, with elevated MICs, that lysed normally with penicillin. We suggest that the cyclic antibiotic exposure generally used in the clinical setting may select primarily for enhanced survival. From these survivors a second type of antibiotic exposure--sustained antibiotic concentrations just above the MIC (concentrations that may be restricted to the tail-end trough of a dosing interval)--selects for penicillin-resistant mutants.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 2897398     DOI: 10.1093/infdis/157.6.1150

Source DB:  PubMed          Journal:  J Infect Dis        ISSN: 0022-1899            Impact factor:   5.226


  21 in total

Review 1.  Bacteriophage lysis: mechanism and regulation.

Authors:  R Young
Journal:  Microbiol Rev       Date:  1992-09

2.  A pneumococcal clinical isolate with high-level resistance to cefotaxime and ceftriaxone.

Authors:  A M Figueiredo; J D Connor; A Severin; M V Vaz Pato; A Tomasz
Journal:  Antimicrob Agents Chemother       Date:  1992-04       Impact factor: 5.191

Review 3.  Continuous infusion of beta-lactam antibiotics.

Authors:  W A Craig; S C Ebert
Journal:  Antimicrob Agents Chemother       Date:  1992-12       Impact factor: 5.191

4.  Two bactericidal targets for penicillin in pneumococci: autolysis-dependent and autolysis-independent killing mechanisms.

Authors:  P Moreillon; Z Markiewicz; S Nachman; A Tomasz
Journal:  Antimicrob Agents Chemother       Date:  1990-01       Impact factor: 5.191

5.  Deregulation of the arginine deiminase (arc) operon in penicillin-tolerant mutants of Streptococcus gordonii.

Authors:  I Caldelari; B Loeliger; H Langen; M P Glauser; P Moreillon
Journal:  Antimicrob Agents Chemother       Date:  2000-10       Impact factor: 5.191

6.  Influence of antibiotic dose, dosing interval, and duration of therapy on outcome in experimental pneumococcal meningitis in rabbits.

Authors:  M G Täuber; S Kunz; O Zak; M A Sande
Journal:  Antimicrob Agents Chemother       Date:  1989-04       Impact factor: 5.191

7.  Amoxicillin is effective against penicillin-resistant Streptococcus pneumoniae strains in a mouse pneumonia model simulating human pharmacokinetics.

Authors:  Pierre Abgueguen; Esther Azoulay-Dupuis; Violaine Noel; Pierre Moine; Veronique Rieux; Bruno Fantin; Jean-Pierre Bedos
Journal:  Antimicrob Agents Chemother       Date:  2006-10-23       Impact factor: 5.191

8.  Pharmacodynamics and bactericidal activity of ceftriaxone therapy in experimental cephalosporin-resistant pneumococcal meningitis.

Authors:  I Lutsar; A Ahmed; I R Friedland; M Trujillo; L Wubbel; K Olsen; G H McCracken
Journal:  Antimicrob Agents Chemother       Date:  1997-11       Impact factor: 5.191

9.  Penicillin-binding proteins 2b and 2x of Streptococcus pneumoniae are primary resistance determinants for different classes of beta-lactam antibiotics.

Authors:  T Grebe; R Hakenbeck
Journal:  Antimicrob Agents Chemother       Date:  1996-04       Impact factor: 5.191

10.  Amoxicillin dose-effect relationship with Streptococcus pneumoniae in a mouse pneumonia model and roles of in vitro penicillin susceptibilities, autolysis, and tolerance properties of the strains.

Authors:  E Azoulay-Dupuis; P Moine; J P Bedos; V Rieux; E Vallee
Journal:  Antimicrob Agents Chemother       Date:  1996-04       Impact factor: 5.191

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.